home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

cGMP: Strategies for implementation and compliance for Phase I Investigational Drug and Biologic products

 
  December 03, 2012  
     
 
ComplianceOnline, Online Event
2013-01-24


This cGMP training will help you in understanding systematic plan of evaluating cGMP applicable to the IND product cycle, the regulatory mandates (FDA, ICH, CHMP and the EU medicine agency), risk-management strategy and potential consequences for failures in inadequate assessment, and case studies of infractions.

 Why Should You Attend:

cGMP guide lines were formulated for the purpose of regulating large-scale manufacturing and commercial drug products. But it is amended in 21 CFR Part 210 for applicability to small-scale laboratory production of exploratory and investigational drug and biologic products. The amended GMP guide lines are a component of the FDA’s “Product Quality for the 21st Century” initiative for a selective approach to varying production objectives during drug development. These exemptions allow the option to the FDA to advise investigators on the safety requirements of laboratory production lots that unequivocally permit administration to human subjects in clinical trials.

This webinar will provide a detailed overview of cGMP regulations for IND drug and biologic products. The applicable requirements from earlier FDA guidance documents will also be addressed. The key differences between cGMP regulations between IND and manufacturing production will be identified to enable streamlining the drug development process through the identification of new, innovative therapies. The comprehensive guidelines of regulatory agencies including the Food and Drug Administration (FDA), the International Conference on Harmonization (ICH), and the Committee for Medicinal Products for Human Use (CHMP)/ the European Medicines Agency will be covered.

In conclusion, this webinar will educate the participant on the broad ranging systematic plan of evaluating cGMP applicable to the IND product cycle, the regulatory mandates, risk-management strategy and potential consequences for failures in inadequate assessment, and case studies of infractions.

Areas Covered in the Seminar:
  • Key aspects of FDA cGMP requirements for IND products.
  • Historical FDA cGMP requirements for drugs and biologics.
  • Practical implications.
  • Regulatory guidelines; FDA, ICH, CHMP, EMEA.

 

 
 
Organized by: ComplianceOnline
Invited Speakers:

Chitra Edwin, Ph.D., RAC., Principal, Biotechnology Consulting Solutions, Ltd. has over 15 years of product development and management experience in start-ups, mid-sized and large biotechnology and diagnostic companies. She has managed projects from concept, R&D through manufacturing transfer, and has been involved in the development of approved products

 
Deadline for Abstracts: 2013-01-24
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=701619?channel=hum-molgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.